Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).

Literature DB >> 1416864

Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).

F T Aweeka¹, J G Gambertoglio, C van der Horst, R Raasch, M A Jacobson.

Abstract

Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1416864 PMCID： PMC192046 DOI： 10.1128/AAC.36.8.1773

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

Review 1. Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors: J M Collins; J D Unadkat
Journal: Clin Pharmacokinet Date: 1989-07 Impact factor: 6.447

2. Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration.

Authors: S L Wong; M A Hedaya; R J Sawchuk
Journal: Pharm Res Date: 1992-02 Impact factor: 4.200

3. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

Authors: M A Jacobson; S Crowe; J Levy; F Aweeka; J Gambertoglio; N McManus; J Mills
Journal: J Infect Dis Date: 1988-10 Impact factor: 5.226

4. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.

Authors: J Sjövall; A Karlsson; S Ogenstad; E Sandström; M Saarimäki
Journal: Clin Pharmacol Ther Date: 1988-07 Impact factor: 6.875

5. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

Authors: F Aweeka; J Gambertoglio; J Mills; M A Jacobson
Journal: Antimicrob Agents Chemother Date: 1989-05 Impact factor: 5.191

6. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.

Authors: M K Hassanzadeh; F T Aweeka; S Wu; M A Jacobson; J G Gambertoglio
Journal: J Chromatogr Date: 1990-01-26

7. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.

Authors: E Singlas; J C Pioger; A M Taburet; J N Colin; J P Fillastre
Journal: Clin Pharmacol Ther Date: 1989-08 Impact factor: 6.875

Review 8. Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.

Authors: M A Jacobson
Journal: Am J Med Date: 1992-02-14 Impact factor: 4.965

9. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.

Authors: K J Pettersson; T Nordgren; D Westerlund
Journal: J Chromatogr Date: 1989-03-24

10. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Authors: J Sjövall; S Bergdahl; G Movin; S Ogenstad; M Saarimäki
Journal: Antimicrob Agents Chemother Date: 1989-07 Impact factor: 5.191

8 in total

Review 8. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors: A J Wagstaff; H M Bryson
Journal: Drugs Date: 1994-08 Impact factor: 9.546

8 in total

Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).

Review 1. Clinical pharmacokinetics of zidovudine. An overview of current data.

2. Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration.

3. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

4. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.

5. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

6. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.

7. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.

Review 8. Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.

9. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography.

10. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

1. Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.

Review 2. Drug interactions with antiviral drugs.

Review 3. Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Review 4. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Review 5. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

6. Penetration of foscarnet into cerebrospinal fluid of AIDS patients.

7. Foscarnet for suppression of human immunodeficiency virus replication.

Review 8. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.